Eric H. Bjerkholt

2017 - Aimmune Therapeutics

In 2017, Eric H. Bjerkholt earned a total compensation of $3.9M as Chief Financial Officer at Aimmune Therapeutics.

Compensation breakdown

Bonus$56,800
Non-Equity Incentive Plan$116,000
Option Awards$3,417,012
Salary$268,333
Total$3,858,145

Bjerkholt received $3.4M in option awards, accounting for 89% of the total pay in 2017.

Bjerkholt also received $56.8K in bonus, $116K in non-equity incentive plan and $268.3K in salary.

Rankings

In 2017, Eric H. Bjerkholt's compensation ranked 2,675th out of 14,666 executives tracked by ExecPay. In other words, Bjerkholt earned more than 81.8% of executives.

ClassificationRankingPercentile
All
2,675
out of 14,666
82nd
Division
Manufacturing
927
out of 5,768
84th
Major group
Chemicals And Allied Products
245
out of 2,074
88th
Industry group
Drugs
187
out of 1,730
89th
Industry
Pharmaceutical Preparations
150
out of 1,329
89th
Source: SEC filing on April 11, 2018.

Bjerkholt's colleagues

We found five more compensation records of executives who worked with Eric H. Bjerkholt at Aimmune Therapeutics in 2017.

2017

Stephen Dilly

Aimmune Therapeutics

Chief Executive Officer

2017

Daniel Adelman

Aimmune Therapeutics

Chief Medical Officer

2017

Douglas Sheehy

Aimmune Therapeutics

General Counsel

2017

Jeffrey Knapp

Aimmune Therapeutics

Chief Operating Officer

2017

Warren DeSouza

Aimmune Therapeutics

Chief Financial Officer

News

In-depth

You may also like